SCHEMBL31268776

SCHEMBL31268776

Cc1ccnc(Cn2c(-c3ccc(CN4CCC(O)CC4)cc3Cl)nc3c(OC4(C)CC4)ncnc32)c1

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ KCNH2 Q12809 1/20 0.41
▸ SCN5A Q14524 1/20 0.41
▸ SCN9A Q15858 1/20 0.41
▸ PDE2A O00408 2/20 0.37
▸ PDE10A Q9Y233 1/20 0.37
▸ PIK3CD O00329 4/20 0.36
▸ CNR1 P21554 4/20 0.34
▸ MCHR1 Q99705 1/20 0.33
▸ S1PR1 P21453 1/20 0.33
▸ ACVR1 Q04771 2/20 0.33
▸ ALDH1A1 P00352 2/20 0.33
▸ KDM4E B2RXH2 1/20 0.33
▸ POLB P06746 1/20 0.33
▸ MEN1 O00255 1/20 0.33
▸ CYP2D6 P10635 1/20 0.33
▸ RAB9A P51151 1/20 0.33
▸ KMT2A Q03164 1/20 0.33
▸ ENPP2 Q13822 1/20 0.32
▸ CCR3 P51677 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31269000 0.96 PDE2A (0.39) KCNH2SCN5ASCN9APDE2APDE10A
SCHEMBL31268817 0.94 KCNH2 (0.38) KCNH2SCN5ASCN9APDE2APDE10A
SCHEMBL31269371 0.93 KCNH2 (0.36) KCNH2SCN5ASCN9APDE2APIK3CD
SCHEMBL31269028 0.91 KCNH2 (0.37) KCNH2SCN5ASCN9APDE2APIK3CD
SCHEMBL31268868 0.90 PIK3CD (0.39) KCNH2SCN5ASCN9APIK3CDCNR1
SCHEMBL31269467 0.88 KCNH2 (0.34) KCNH2SCN5ASCN9APIK3CD
SCHEMBL31269300 0.87 DGAT1 (0.41) KCNH2SCN5ASCN9APIK3CD
SCHEMBL31269121 0.87 PIK3CD (0.40) KCNH2SCN5ASCN9APIK3CDCNR1
SCHEMBL31268930 0.86 KCNH2 (0.34) KCNH2SCN5ASCN9APDE10APIK3CD
SCHEMBL31269054 0.85 KCNH2 (0.34) KCNH2SCN5ASCN9APDE2APDE10A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4689155-A1 USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS Astrazeneca AB (SE) 2026-02-11 — — EP disclosed
WO-2024201368-A1 USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS ASTRAZENECA AB (SE) 2024-10-03 — — WO disclosed
Send feedback